貨號：GS40117

Cantuzumab mertansine is an investigational antibody-drug conjugate (ADC) that was developed for the treatment of solid tumors, particularly those expressing a specific tumor-associated antigen. It combines a humanized monoclonal antibody with a potent cytotoxic agent (DM1, a maytansine derivative) via a cleavable linker. Early clinical trials focused on cancers such as colorectal, pancreatic, and non-small cell lung cancer, but its development appears to have been discontinued due to limited efficacy or strategic portfolio decisions in later-phase studies.